respiratori
infect
usual
divid
involv
upper
involv
lower
respiratori
tract
former
typic
includ
infect
sinus
tonsillopharyng
area
middl
ear
lower
respiratori
tract
infect
includ
acut
bronchiti
acut
exacerb
chronic
bronchiti
pneumonia
pneumonia
subdivid
communityacquir
healthcareassoci
hospitalacquir
infect
acut
lower
respiratori
tract
infect
signific
caus
morbid
mortal
worldwid
occur
develop
countri
poverti
inadequ
medic
care
contribut
high
mortal
rate
pneumonia
continu
common
caus
death
infecti
diseas
worldwid
although
understand
variou
etiolog
agent
pathogen
mechan
involv
variou
respiratori
infect
increas
abil
diagnos
accur
caus
agent
kept
pace
mean
often
physician
initi
treatment
empir
basi
far
mani
situat
antibiot
use
infect
viral
natur
lower
respiratori
tract
infect
typic
divid
either
bronchiti
pneumonia
also
thought
infect
involv
airway
pulmonari
parenchyma
respect
acut
bronchiti
common
view
one
end
continuum
extend
bronchiti
pneumonia
gener
particularli
seriou
infect
still
consider
econom
impact
frequenc
physician
visit
fact
despit
lack
compel
evid
support
antimicrobi
therapi
physician
diagnos
acut
bronchiti
prescrib
antibiot
patient
usa
estim
acut
bronchiti
result
approxim
visit
physician
per
year
cost
million
common
infecti
agent
virus
typic
respiratori
virus
rhinoviru
corona
viru
adenoviru
influenza
viru
implic
viral
agent
includ
respiratori
syncyti
viru
rsv
parainfluenza
viru
measl
viru
herp
simplex
viru
term
atyp
respiratori
pathogen
includ
larg
divers
number
etiolog
agent
convent
usual
refer
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
speci
mycoplasma
ch
pneumonia
etiolog
agent
whoop
cough
bordetella
pertussi
commonli
encount
nonvir
caus
acut
bronchiti
like
mani
respiratori
infect
acut
bronchiti
common
winter
month
mean
attack
rate
develop
countri
case
per
person
per
week
reach
peak
case
per
winter
season
case
acut
bronchiti
diseas
process
limit
mucou
membran
line
tracheobronchi
tree
mucou
membran
becom
edemat
hyperem
increas
bronchial
secret
typic
seen
epitheli
injuri
usual
mild
moder
case
influenza
viru
infect
may
fairli
signific
epitheli
damag
studi
pulmonari
function
attack
acut
bronchiti
demonstr
abnorm
find
airway
resist
reactiv
result
keep
associ
describ
increas
incid
mild
asthma
patient
histori
recurr
episod
acut
bronchiti
increas
airway
reactiv
resist
may
manifest
clinic
persist
cough
last
sever
week
follow
initi
infect
predomin
symptom
cough
may
last
sever
week
depend
upon
etiolog
agent
may
nonproduct
product
either
mucoid
purul
sputum
case
sputum
may
mucoid
initi
secondari
bacteri
infect
result
may
becom
purul
patient
may
also
experi
burn
retrostern
sensat
inspir
physic
examin
may
reveal
presenc
rhonchi
coars
rale
bronchial
breath
sound
heard
patient
may
febril
usual
appear
particularli
ill
except
herp
simplex
infect
bronchiti
complic
influenza
produc
mark
malais
diagnosi
acut
bronchiti
otherwis
well
adult
usual
obviou
clinic
featur
question
pneumonia
chest
radiograph
exclud
presenc
pulmonari
infiltr
gener
worth
obtain
blood
sampl
serolog
sputum
gram
stain
cultur
treatment
acut
bronchiti
common
condit
patient
manag
home
treatment
acut
bronchiti
symptomat
specif
symptomat
treatment
reli
primarili
upon
mainten
adequ
hydrat
cough
suppress
unabl
sleep
bronchospasm
problem
inhal
adrenerg
bronchodil
may
use
present
evid
support
routin
use
oral
inhal
steroid
smoker
encourag
stop
patient
underli
cardiopulmonari
diseas
episod
acut
bronchiti
may
precipit
cardiac
failur
patient
may
need
admit
hospit
appropri
ventilatori
cardiac
support
antimicrobi
chemotherapi
gener
recommend
number
placebocontrol
trial
evalu
role
antibiot
acut
bronchiti
minim
benefit
best
antibiot
might
consid
patient
persist
prolong
worsen
symptom
situat
doxycyclin
macrolid
erythromycin
azithromycin
clarithromycin
consid
chronic
bronchiti
defin
presenc
product
cough
least
month
year
consecut
year
chronic
bronchiti
constitut
common
compon
chronic
obstruct
pulmonari
diseas
copd
clinic
entiti
character
reduc
expiratori
air
flow
rel
stabl
sever
month
observ
prognosi
copd
correl
best
forc
expiratori
volum
one
second
fev
fall
predict
valu
prognosi
worsen
physician
differenti
among
copd
acut
bronchiti
acut
exacerb
chronic
bronchiti
aecb
fact
even
pneumonia
often
simpli
includ
part
design
lower
respiratori
tract
infect
difficult
obtain
accur
data
exact
econom
impact
entiti
although
copd
estim
afflict
onefifth
popul
usa
uk
around
million
work
day
lost
everi
year
bronchiti
diseas
account
approxim
death
annual
chronic
bronchiti
result
varieti
insult
lung
time
includ
predominantli
cigarett
smoke
infect
environment
pollut
irrit
chronic
bronchiti
establish
episod
worsen
refer
acut
exacerb
chronic
bronchiti
trigger
similar
caus
purpos
chapter
howev
focu
infecti
trigger
virus
account
acut
exacerb
chronic
bronchiti
varieti
agent
implic
rsv
rhinoviru
influenza
viru
parainfluenza
viru
remain
acut
exacerb
bacteri
natur
common
pathogen
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
role
atyp
pathogen
pneumonia
ch
pneumonia
unclear
thought
may
account
small
percentag
infect
infect
result
releas
inflammatori
mediat
impair
mucociliari
clearanc
turn
alter
local
milieu
make
easier
pathogen
colon
airway
progress
airway
damag
thought
occur
result
injuri
caus
either
pathogen
host
respons
variou
infect
agent
clinic
manifest
patient
aecb
repres
common
pathway
underli
pulmonari
diseas
form
chronic
bronchiti
emphysema
acut
exacerb
trigger
infect
environment
pollut
patient
may
present
follow
increas
dyspnea
sputum
volum
sputum
purul
anthonisen
colleagu
demonstr
patient
least
two
three
find
experienc
better
clinic
outcom
treat
antibiot
placebo
anthonisen
classif
refer
patient
one
find
type
two
find
type
three
find
type
symptom
may
note
exacerb
includ
wheez
elev
temperatur
feel
malais
durat
exacerb
vari
day
sever
week
averag
patient
experi
approxim
three
exacerb
annual
although
signific
variat
describ
diagnosi
aecb
usual
clinic
patient
known
histori
chronic
bronchiti
suffer
period
flareup
usual
well
awar
sign
symptom
herald
onset
exacerb
increas
dyspnea
sputum
volum
purul
main
clue
exacerb
occur
one
difficulti
defin
etiolog
mani
individu
chronic
bronchiti
normal
bacteria
respiratori
secret
bacteria
colon
airway
exacerb
present
higher
number
h
influenza
str
pneumonia
mor
catarrhali
predomin
pathogen
howev
among
sever
exacerb
requir
admiss
intens
care
unit
icu
mechan
ventil
pathogen
seem
present
less
frequent
organ
h
parainfluenza
pseudomona
aeruginosa
frequent
found
bacteria
context
often
resist
antibiot
patient
treatment
begun
empir
sever
underli
diseas
exacerb
appear
seriou
may
worthwhil
obtain
sputum
sampl
cultur
suscept
test
order
rule
presenc
resist
pathogen
data
avail
suggest
sever
ill
increas
indic
marker
ill
last
longer
year
four
exacerb
per
year
steroid
therapi
recent
antibiot
sever
airway
obstruct
fev
predict
microbiolog
becom
complex
basi
clinic
examin
may
imposs
differenti
acut
exacerb
chronic
bronchiti
pneumonia
case
chest
radiograph
necessari
anthonisen
first
assess
respons
treatment
base
upon
stratif
patient
accord
symptom
metaanalysi
nine
random
placebocontrol
trial
patient
treat
aecb
demonstr
statist
signific
improv
outcom
treat
antibiot
effect
size
favor
antibiot
seven
nine
studi
despit
data
howev
clear
routin
antibiot
treatment
fail
exacerb
failur
carri
econom
burden
requir
addit
visit
physician
addit
treatment
regimen
day
lost
work
number
risk
factor
defin
treatment
failur
includ
presenc
cardiopulmonari
diseas
increas
frequenc
pulmonari
infect
previou
year
subgroup
patient
risk
treatment
failur
also
respiratori
failur
mortal
rate
hospit
inpati
describ
typic
patient
older
year
comorbid
respiratori
extrapulmonari
organ
dysfunct
resid
hospit
transfer
icu
suggest
stratif
patient
accord
risk
factor
allow
physician
treat
appropri
singl
stratif
scheme
agre
upon
exist
attempt
rank
patient
accord
increas
risk
factor
treatment
failur
possibl
admiss
hospit
three
schema
publish
date
lode
germani
balter
canada
wilson
uk
recommend
summar
tabl
patient
aecb
consid
possibl
infect
core
group
pathogen
h
influenza
str
pneumonia
mor
catarrhali
complic
elderli
patient
patient
frequent
exacerb
reduc
lung
function
may
infect
core
pathogen
also
gramneg
bacilli
enterobacteriacea
ps
aeruginosa
possibl
resist
core
pathogen
advantag
approach
lie
fact
identifi
patient
increas
risk
failur
treatment
may
initi
antibiot
regimen
like
effect
potenti
etiolog
pathogen
varieti
adjunct
support
measur
includ
use
bronchodil
steroid
oral
andor
inhal
oxygen
therapi
may
necessari
prevent
measur
cessat
smoke
annual
influenza
vaccin
administr
pneumococc
vaccin
emphas
communityacquir
pneumonia
cap
signific
impact
individu
patient
societi
pneumonia
current
sixth
lead
caus
death
usa
estim
million
case
annual
account
hospit
admiss
million
day
restrict
activ
cap
report
diseas
exact
figur
avail
clear
howev
signific
impact
individu
patient
societi
whole
patient
treat
outpati
admit
hospit
gener
cost
annual
cost
treatment
us
billion
patient
older
year
billion
patient
year
mani
infect
incid
rate
cap
greatest
extrem
age
although
overal
annual
rate
pneumonia
usa
case
per
rate
case
per
children
year
age
case
per
peopl
year
age
age
year
annual
rate
rang
one
five
case
per
incid
cap
requir
admiss
hospit
adult
patient
case
per
risk
factor
pneumonia
defin
includ
follow
alcohol
asthma
immunosuppress
institution
age
greater
equal
year
versu
age
year
specif
risk
factor
pneumococc
infect
includ
dementia
seizur
disord
congest
heart
failur
cerebrovascular
diseas
copd
hiv
infect
numer
microbi
pathogen
potenti
etiolog
agent
patient
may
infect
one
agent
mix
infect
well
describ
hospitalacquir
pneumonia
multipl
pathogen
present
half
nosocomi
pneumonia
patient
studi
cap
incid
mix
infect
lower
rang
welldefin
studi
inpati
cap
singl
import
etiolog
agent
undoubtedli
str
pneumonia
metaanalysi
cover
period
includ
case
pneumonia
etiolog
diagnosi
made
str
pneumonia
account
twothird
case
twothird
fatal
one
time
thought
atyp
pathogen
pneumonia
ch
pneumonia
legionella
speci
import
caus
pneumonia
caus
infect
usual
mild
affect
primarili
young
studi
patient
admit
hospit
cap
rank
pathogen
second
third
fourth
etiolog
agent
meet
criteria
definit
diagnosi
anoth
studi
describ
three
outbreak
ch
pneumonia
nurs
home
high
attack
mortal
rate
two
studi
help
dispel
earlier
misconcept
surround
infect
atyp
pathogen
gramneg
rod
escherichia
coli
klebsiella
spp
particularli
common
caus
cap
nevertheless
import
consid
particularli
elderli
peopl
comorbid
ill
especi
ill
enough
requir
hospit
treatment
consider
debat
whether
ps
aeruginosa
signific
pathogen
requir
treatment
consensu
certainli
common
occur
select
patient
risk
factor
recent
cours
antibiot
steroid
prolong
stay
hospit
present
variou
etiolog
pathogen
gain
access
lower
respiratori
tract
number
possibl
rout
includ
inhal
aspir
hematogen
spread
bacteri
pneumonia
aspir
organ
colon
oropharynx
appear
import
rout
pneumonia
result
innat
immun
includ
macrophag
phagocytosi
fail
erad
infect
pathogen
neutrophil
infiltr
recruit
rel
recent
physician
tend
divid
case
cap
typic
atyp
pneumonia
base
upon
clinic
present
typic
classic
pneumonia
refer
infect
caus
bacteri
pathogen
str
pneumonia
h
influenza
wherea
atyp
pneumonia
refer
infect
caus
atyp
pathogen
pneumonia
ch
pneumonia
legionella
spp
thought
classic
bacteri
pneumonia
present
fairli
sudden
onset
sign
symptom
cough
product
purul
sputum
pleurit
chest
pain
rigor
contrast
atyp
infect
present
ill
undefin
durat
nonproduct
cough
often
frontal
headach
becom
clear
howev
possibl
determin
etiolog
agent
care
histori
physic
examin
nonspecif
laboratori
test
chest
radiograph
symptom
cap
may
constitut
nonspecif
may
local
respiratori
tract
fairli
specif
respiratori
infect
former
categori
includ
find
malais
anorexia
myalgia
arthralgia
chill
rigor
latter
includ
short
breath
pleurit
chest
pain
cough
sputum
product
elderli
patient
find
may
imprecis
constitut
symptom
confus
may
predomin
may
fewer
find
relat
respiratori
tract
problem
diagnosi
cap
gener
much
debat
among
physician
unfortun
despit
extens
test
even
univers
medic
center
specif
etiolog
agent
may
found
onehalf
case
routin
clinic
practic
etiolog
agent
determin
approxim
case
result
chang
antimicrobi
therapi
less
case
furthermor
improv
clinic
outcom
alway
result
identif
etiolog
agent
gener
diagnost
test
fall
two
categori
clinic
invasivequantit
clinic
test
reli
inform
obtain
patient
histori
physic
examin
select
test
procedur
chest
radiographi
sputum
gram
stain
blood
sputum
cultur
invasivequantit
method
includ
bronchoscop
techniqu
pleural
fluid
aspir
select
case
lung
biopsi
rule
clinic
method
sensit
lack
specif
invasivequantit
method
requir
special
expertis
laboratori
support
costli
first
step
determin
whether
patient
pneumonia
rather
infect
process
bronchiti
whether
noninfecti
etiolog
eg
congest
heart
failur
pulmonari
embol
caus
patient
problem
diagnosi
pneumonia
made
next
step
determin
etiolog
agent
possibl
unfortun
imposs
accur
identifi
pathogen
base
clinic
find
even
multipl
clinic
variabl
use
signific
intraobserv
variat
abil
elicit
abnorm
physic
find
sensit
specif
histori
physic
examin
current
undetermin
presenc
infiltr
chest
radiograph
help
establish
diagnosi
pneumonia
determin
caus
pathogen
howev
radiograph
import
defin
presenc
lobar
multilobar
infiltr
assess
sever
ill
prognosi
routin
laboratori
assess
unnecessari
ambulatori
patient
cap
like
manag
outpati
howev
ill
enough
requir
admiss
hospit
even
consid
admiss
complet
blood
differenti
count
serum
electrolyt
liver
function
test
serum
creatinin
oxygen
satur
assess
obtain
signific
abnorm
identifi
risk
factor
complic
cours
increas
mortal
abnorm
use
assess
mortal
risk
help
site
care
decis
two
test
sputum
gram
stain
reliabl
regard
neither
sensit
specif
though
laboratori
test
made
posit
contribut
earli
diagnosi
mani
patient
unabl
produc
sputum
sampl
sampl
produc
signific
percentag
may
adequ
although
current
data
suggest
atyp
pathogen
respons
cap
case
none
detect
sputum
gram
stain
also
consider
interand
intraobserv
variat
gram
stain
interpret
sputum
cultur
also
lack
sensit
specif
even
patient
confirm
pneumococc
pneumonia
base
upon
posit
blood
cultur
simultan
obtain
sputum
cultur
test
posit
onehalf
patient
incid
posit
blood
cultur
ambulatori
patient
cap
less
hospit
inpati
rang
may
reach
patient
icu
common
pathogen
str
pneumonia
pneumococc
pneumonia
complic
bacteremia
frequent
pneumonia
caus
pathogen
gener
recommend
blood
cultur
obtain
patient
admit
cap
treat
commun
determin
role
specif
microorgan
pathogen
serolog
assess
base
result
pair
acut
convalesc
serum
sampl
unfortun
result
never
avail
time
initi
treatment
decis
made
therefor
help
defin
epidemiolog
role
select
pathogen
serolog
test
help
recommend
routin
use
test
easi
perform
yield
rapid
result
sensit
specif
limit
fact
identifi
legionella
pneumophila
serogroup
howev
serogroup
account
legionella
infect
polymeras
chain
reactionbas
method
use
increasingli
unfortun
rapid
diagnost
techniqu
gener
avail
simpli
identifi
presenc
particular
microorgan
confirm
infect
howev
microorgan
whose
mere
presenc
indic
infect
includ
tuberculosi
coxiella
burnetii
pneumocysti
jirovecii
formerli
pn
carinii
patient
cap
invas
test
bronchoscopi
bronchoalveolar
lavag
protect
specimen
brush
percutan
lung
needl
aspir
requir
howev
may
appropri
certain
situat
eg
patient
fulmin
pneumonia
unrespons
standard
cours
antimicrobi
may
necessari
identifi
resist
fastidi
pathogen
rule
noninfecti
caus
thoracocentesi
perform
cap
patient
signific
pleural
effus
defin
collect
greater
mm
thick
later
decubitu
view
incid
pleural
effus
pneumonia
vari
common
patient
pneumococc
infect
treatment
therapi
direct
empir
direct
therapi
impli
etiolog
agent
known
therapi
aim
specif
pathogen
empir
therapi
usual
effect
educ
guess
physician
institut
cours
treatment
aim
like
caus
two
option
direct
therapi
clearli
desir
limit
breadth
spectrum
requir
treatment
agent
may
limit
number
drug
reduc
advers
reaction
associ
antibiot
reduc
antibiot
select
pressur
may
result
less
antimicrobi
resist
discuss
variou
regimen
import
consid
decis
made
term
outpati
versu
inpati
therapi
problem
antimicrobi
resist
decis
import
one
consider
econom
implic
cost
inpati
care
exce
outpati
treatment
factor
cost
hospit
manag
account
money
spent
annual
cap
usa
case
immedi
obviou
patient
treat
outsid
hospit
situat
equal
appar
patient
requir
hospit
treatment
possibl
admiss
icu
effect
prognost
score
outcom
assess
tool
necessari
help
physician
make
site
care
decis
tool
provid
object
method
assess
risk
advers
outcom
includ
death
studi
fine
other
attempt
identifi
patient
increas
risk
advers
outcom
defin
independ
predictor
mortal
poor
outcom
howev
weak
design
flaw
found
use
predict
rule
may
minim
unnecessari
hospit
admiss
help
identifi
patient
benefit
care
intervent
hospit
icu
best
known
wide
use
prognost
tool
fine
twostep
rule
design
identifi
patient
low
risk
mortal
point
given
base
age
coexist
diseas
abnorm
physic
laboratori
find
patient
assign
class
base
total
number
point
assign
score
system
use
triag
lowrisk
patient
toward
outpati
therapi
high
degre
success
fine
rule
adopt
recommend
publish
infecti
diseas
societi
america
idsa
american
thorac
societi
at
european
respiratori
societi
altern
system
assess
sever
curb
score
recommend
british
thorac
societi
european
respiratori
societi
score
incorpor
assess
puls
rate
respiratori
rate
renal
function
mental
statu
initi
evalu
patient
assign
point
abnorm
featur
plu
patient
year
age
variat
much
easier
use
fine
score
assess
patient
sever
score
system
guid
ultim
physician
must
decid
ground
clinic
experi
whether
individu
patient
pneumonia
warrant
intraven
therapi
admiss
hospit
manag
intens
care
facil
antimicrobi
resist
among
respiratori
pathogen
becom
major
concern
import
clinician
understand
appreci
gener
mechan
implic
phenomenon
emerg
resist
penicillin
among
str
pneumonia
isol
repres
gradual
reduct
invitro
suscept
nation
committe
clinic
laboratori
standard
defin
strain
minimum
inhibitori
concentr
mic
penicillin
mgl
sensit
mgl
intermedi
mgl
resist
str
pneumonia
dna
incorpor
remodel
result
resist
dna
close
relat
oral
commens
bacteria
see
ch
process
flora
develop
resist
treat
antibiot
pathogen
str
pneumonia
subsequ
acquir
resist
code
dna
colon
microflora
pneumococc
resist
due
sole
presenc
lowaffin
penicillinbind
protein
macrolid
resist
howev
occur
either
target
site
modif
efflux
pump
see
ch
rel
frequenc
two
mechan
vari
intern
north
america
account
approxim
respect
resist
isol
report
breakthrough
pneumococc
bacteremia
patient
treat
macrolid
highlight
concern
resist
class
agent
resist
ciprofloxacin
newer
fluoroquinolon
among
pneumococc
isol
report
pneumococc
resist
fluoroquinolon
may
mediat
chang
one
target
site
topoisomeras
ii
iv
usual
result
mutat
gyra
parc
gene
respect
possibl
also
efflux
pump
see
ch
greatest
concern
howev
multidrugresist
isol
resist
two
antibiot
differ
mechan
action
usa
proport
invas
pneumococc
isol
resist
three
class
drug
increas
also
increas
proport
isol
resist
penicillin
cefotaxim
meropenem
erythromycin
trimethoprimsulfamethoxazol
increas
frequenc
resist
multipl
antimicrobi
agent
occur
penicillinresist
isol
drugresist
str
pneumonia
associ
variou
risk
factor
includ
presenc
comorbid
chronic
heart
lung
liver
renal
diseas
diabet
alcohol
immunosuppress
use
antimicrobi
within
previou
month
infect
drugresist
pneumococci
result
invas
diseas
higher
mortal
rate
amongst
hospit
individu
pathogen
h
influenza
enterobacteriacea
also
import
consid
h
influenza
third
common
caus
cap
requir
admiss
hospit
enterobacteriacea
particularli
common
import
high
mortal
rate
associ
among
pathogen
resist
usual
mediat
highest
preval
gene
found
plasmid
rather
chromosom
member
tem
shv
famili
success
plasmidencod
account
almost
plasmidencod
extendedspectrum
includ
oxyimino
enzym
tem
shv
mutant
cephalosporinas
unrel
tem
shv
enzym
see
ch
diagnosi
pneumonia
made
physician
must
decid
whether
treat
patient
outsid
insid
hospit
turn
help
determin
appropri
therapeut
regimen
patient
empir
choic
must
made
howev
infect
pathogen
known
antibiot
choic
guid
local
knowledg
antimicrobi
sensit
polici
correct
choic
antimicrobi
empir
therapi
gener
consider
discuss
number
societi
produc
guidelin
help
physician
initi
manag
patient
cap
guidelin
serv
number
use
function
codifi
manag
patient
cap
least
highlight
gap
knowledg
help
direct
futur
studi
research
adher
guidelin
signific
pharmacoeconom
effect
lower
mortal
rate
shorten
hospit
stay
joint
guidelin
idsa
at
make
recommend
outpati
inpati
treatment
pneumonia
draw
distinct
individu
risk
factor
drugresist
str
pneumonia
drsp
tabl
outpati
treatment
previous
healthi
individu
risk
factor
drsp
guidelin
recommend
macrolid
azithromycin
clarithromycin
erythromycin
doxycyclin
presenc
risk
factor
drsp
outpati
recommend
respiratori
fluoroquinolon
moxifloxacin
gemifloxacin
levofloxacin
mg
high
dose
plu
macrolid
doxycyclin
latter
recommend
also
pertain
inpati
nonicu
inpati
requir
icu
treatment
idsaat
guidelin
recommend
cefotaxim
ceftriaxon
ampicillinsulbactam
plu
either
azithromycin
fluoroquinolon
except
pseudomona
infect
suspect
case
antipneumococc
antipseudomon
piperacillintazobactam
cefepim
imipenem
meropenem
plu
either
ciprofloxacin
levofloxacin
mg
recommend
firstlin
regimen
communityacquir
methicillinresist
staphylococcu
aureu
infect
suspect
caus
pneumonia
guidelin
recommend
addit
vancomycin
linezolid
regimen
recommend
use
macrolid
guidelin
relat
coverag
atyp
pathogen
would
agent
choic
str
pneumonia
would
ineffect
atyp
howev
macrolid
provid
goodtoexcel
coverag
like
pathogen
north
america
fluoroquinolon
assum
import
role
manag
cap
coincid
rise
resist
macrolid
appreci
potenti
import
gramneg
rod
select
cap
patient
avail
respiratori
fluoroquinolon
offer
oncedaili
monotherapi
compar
multipl
dose
requir
macrolid
regimen
use
mani
expert
feel
penicillin
still
role
play
treatment
pneumococc
pneumonia
effect
infect
caus
suscept
organ
strain
str
pneumonia
intermedi
level
resist
penicillin
higher
dose
may
use
recommend
idsaat
guidelin
unfortun
ident
suscept
etiolog
agent
unknown
case
time
initi
antibiot
treatment
efflux
resist
macrolid
result
lowlevel
resist
wherea
target
chang
mechan
result
highlevel
resist
lowlevel
resist
predomin
north
america
latter
frequent
europ
usa
canada
therefor
macrolid
still
seen
signific
role
play
manag
mani
patient
cap
treat
hospit
guidelin
divid
patient
treat
medic
ward
treat
icu
use
risk
infect
ps
aeruginosa
mean
subdivid
icu
patient
reflect
enhanc
mortal
rate
constitut
antimicrobi
resist
associ
organ
recent
british
thorac
societi
bt
guidelin
tabl
provid
exhaust
evidencebas
approach
manag
cap
patient
differ
idsaat
guidelin
quit
extens
outpati
bt
consid
atyp
pathogen
pneumonia
ch
pneumonia
import
enough
warrant
routin
coverag
therefor
treatment
aim
primarili
str
pneumonia
drug
choic
amoxicillin
hospit
inpati
north
american
document
divid
patient
manag
ward
icu
wherea
british
guidelin
consid
hospitaltr
patient
three
categori
sever
admit
nonclin
reason
previous
treat
commun
moder
sever
outpati
treatment
previous
healthi
use
antimicrobi
within
previou
month
macrolid
doxycyclin
presenc
comorbid
chronic
heart
lung
liver
renal
diseas
diabet
mellitu
alcohol
malign
asplenia
immunosuppress
condit
use
immunosuppress
drug
use
antimicrobi
within
previou
month
case
altern
differ
class
select
respiratori
fluoroquinolon
moxifloxacin
gemifloxacin
levofloxacin
mg
plu
macrolid
region
high
rate
infect
highlevel
mic
macrolideresist
streptococcu
pneumonia
consid
use
altern
agent
list
patient
without
comorbid
respiratori
fluoroquinolon
plu
macrolid
cefotaxim
ceftriaxon
ampicillinsulbactam
plu
either
azithromycin
respiratori
fluoroquinolon
penicillinallerg
patient
respiratori
fluoroquinolon
aztreonam
recommend
pseudomona
consider
antipneumococc
antipseudomon
piperacillintazobactam
cefepim
imipenem
meropenem
plu
either
ciprofloxacin
levofloxacin
mg
plu
aminoglycosid
azithromycin
plu
aminoglycosid
antipneumococc
fluoroquinolon
penicillinallerg
patient
substitut
aztreonam
camrsa
consider
add
vancomycin
linezolid
admit
nonclin
reason
previous
treat
commun
moder
sever
sever
first
group
treat
amoxicillin
second
given
amoxicillin
plu
macrolid
erythromycin
clarithromycin
third
group
given
amoxicillinclavulan
plu
intraven
erythromycin
clarithromycin
fluoroquinolon
recommend
altern
second
third
categori
gener
potenc
breadth
intraven
antibiot
recommend
increas
sever
increas
moder
ill
hospit
patient
treat
uk
simpl
combin
macrolid
like
use
clinician
follow
bt
guidelin
individu
hospit
polici
tailor
balanc
requir
potent
therapi
need
keep
antimicrobi
activ
narrow
spectrum
possibl
avoid
potenti
impact
hospit
ecolog
initi
treatment
delay
particularli
deal
patient
year
age
studi
elderli
patient
present
emerg
depart
cap
show
receiv
antibiot
within
h
present
significantli
lower
mortal
rate
wait
longer
initi
treatment
intraven
oral
sequenti
treatment
strongli
recommend
reduc
cost
encourag
patient
mobil
allow
earlier
discharg
hospit
ancillari
measur
supplement
oxygen
drainag
signific
pleural
effus
hydrat
also
import
patient
follow
object
paramet
monitor
includ
resolut
cough
short
breath
elev
temperatur
hospit
improv
oxygen
satur
creactiv
protein
white
blood
cell
count
staphylococc
pneumonia
associ
necrot
pneumon
particularli
stain
express
pantonvalentin
leukocidin
toxin
implic
organ
strongli
suspect
patient
sever
pneumonia
combin
intraven
linezolid
mg
everi
h
intraven
clindamycin
g
everi
h
intraven
rifampicin
rifampin
mg
everi
h
ad
initi
antibiot
regimen
healthcareassoci
pneumonia
refer
pneumonia
patient
recent
hospit
hemodialysi
receiv
intraven
chemotherapi
resid
nurs
home
longterm
care
facil
distinguish
differ
pattern
microbi
flora
associ
pneumonia
often
gramposit
organ
higher
tendenc
toward
antimicrobi
resist
also
sever
diseas
longer
hospit
stay
higher
mortal
rate
domin
group
class
patient
gener
compris
resid
nurs
home
nurs
home
pneumonia
pneumonia
elderli
resid
longterm
care
facil
import
entiti
becom
subject
seriou
clinic
investig
pneumonia
main
caus
death
among
resid
facil
acut
mortal
rate
rang
per
infect
common
reason
transfer
nurs
home
resid
acut
care
hospit
approxim
onethird
pneumonia
patient
requir
hospit
admiss
incid
pneumonia
among
resid
nurs
home
consider
higher
among
person
live
commun
rang
episod
per
resid
day
median
incid
per
resid
day
one
difficulti
establish
etiolog
nurs
home
pneumonia
fact
studi
area
depend
almost
exclus
result
sputum
cultur
studi
compromis
outset
half
elderli
patient
produc
sputum
like
pathogen
somewhat
differ
patient
cap
case
cap
predomin
etiolog
agent
str
pneumonia
atyp
select
case
gramneg
rod
may
encount
nurs
home
pneumonia
str
pneumonia
still
signific
pathogen
import
note
age
year
resid
nurs
home
identifi
risk
factor
penicillinresist
str
pneumonia
infect
greater
proport
case
caus
staph
aureu
h
influenza
gramneg
rod
popul
younger
cohort
disconcertingli
high
percentag
staph
aureu
isol
methicillin
resist
atyp
common
younger
patient
role
anaerob
still
definit
settl
appropri
design
studi
substanti
role
pathogen
elderli
appear
undertaken
addit
aerob
possibl
anaerob
bacteri
pathogen
virus
tuberculosi
must
also
consid
epidem
influenza
rsv
parainfluenza
describ
popul
must
alway
consid
institut
outbreak
encount
incid
tuberculosi
substanti
higher
institution
elderli
must
includ
assess
patient
number
risk
factor
defin
prospect
cohort
studi
respiratori
tract
infect
nurs
home
resid
older
age
male
sex
inabl
take
oral
medic
swallow
difficulti
identifi
independ
risk
factor
develop
pneumonia
swallow
difficulti
confus
alter
level
conscious
often
evok
surrog
marker
aspir
infer
indic
infect
anaerob
nasogastr
tube
feed
tracheostomi
also
identifi
potenti
risk
factor
pneumonia
presum
increas
risk
aspir
physician
must
awar
elderli
patient
pneumonia
rather
histori
elev
temperatur
chill
cough
purul
sputum
stori
may
confus
weak
anorexia
fall
difficulti
make
diagnosi
pneumonia
nurs
home
popul
enhanc
fact
nurs
home
lack
laboratori
radiograph
facil
mani
often
physician
attend
fulltim
basi
ideal
patient
present
find
suggest
pneumonia
evalu
physician
chest
radiograph
obtain
feasibl
expector
sputum
sampl
sent
gram
stain
cultur
peopl
seriou
ill
parenter
therapi
transfer
hospit
contempl
follow
addit
test
done
blood
sampl
cultur
suscept
test
complet
blood
count
differenti
serum
creatinin
urin
legionella
antigen
pneumonia
occur
set
influenza
outbreak
particular
case
suggest
influenza
infect
nasopharyng
swab
obtain
rapid
detect
viral
antigen
polymeras
chain
reaction
similarli
tuberculosi
possibl
sputum
sampl
microscopi
rapid
cultur
obtain
circumst
respiratori
precaut
must
institut
patient
isol
prevent
spread
diseas
patient
use
antimicrobi
direct
known
pathogen
ideal
howev
time
treatment
decis
made
unlik
definit
etiolog
agent
identifi
case
pneumonia
empir
regimen
usual
select
base
upon
local
epidemiolog
suscept
pattern
risk
stratif
patient
site
care
decis
import
one
nurs
home
resid
pneumonia
evalu
use
predict
rule
hospit
admiss
use
patient
cap
patient
treat
nurs
home
set
risk
factor
multidrugresist
pathogen
respiratori
fluoroquinolon
moxifloxacin
gatifloxacin
levofloxacin
accord
avail
combin
regimen
consist
amoxicillinclavulan
gener
recommend
first
choic
influenza
outbreak
institut
set
associ
high
attack
rate
mortal
rate
annual
immunoprophylaxi
use
vaccin
offer
protect
recommend
resid
zanamivir
oseltamivir
neuraminidas
inhibitor
activ
influenza
influenza
b
agent
approv
treatment
uncompl
influenza
given
within
h
onset
symptom
may
decreas
sever
durat
symptom
hospitalacquir
nosocomi
pneumonia
definit
infect
occur
h
admiss
hospit
although
second
common
nosocomi
infect
usa
account
hospitalacquir
infect
one
frequent
associ
fatal
outcom
associ
signific
morbid
mortal
current
figur
base
estim
hospit
record
nosocomi
pneumonia
report
diseas
consid
howev
current
case
occur
annual
usa
result
averag
increas
length
hospit
stay
day
mortal
figur
rang
howev
relev
attribut
mortal
figur
estim
estim
rate
occurr
episod
per
hospit
admiss
nonteach
hospit
per
teach
hospit
patient
intub
rate
time
higher
nonintub
patient
rate
ventilatorassoci
pneumonia
report
approxim
per
ventil
day
risk
factor
nosocomi
pneumonia
includ
increas
age
copd
neuromuscular
diseas
decreas
conscious
aspir
endotrach
intub
thorac
upper
abdomin
surgeri
nasogastr
intub
variou
pathogen
perhap
import
defin
risk
factor
staph
aureu
head
injuri
coma
longer
h
intraven
drug
use
ps
aeruginosa
prior
antibiot
structur
lung
diseas
steroid
treatment
common
pathogen
encount
nosocomi
pneumonia
gramneg
bacilli
report
case
staph
aureu
report
patient
infect
occur
first
day
hospit
stay
bacteria
typic
associ
cap
str
pneumonia
h
influenza
also
report
gramneg
rod
interest
esch
coli
klebsiella
spp
enterobact
spp
proteu
spp
serratia
marcescen
esch
coli
third
common
coliform
isol
patient
nosocomi
pneumonia
appear
affect
predispos
host
critic
ill
k
pneumonia
commonli
isol
klebsiella
speci
may
caus
sever
necrot
lobar
pneumonia
elderli
alcohol
diabet
k
pneumonia
esch
coli
bacteria
commonli
carri
extendedspectrum
render
resist
oxyimino
cefotaxim
ceftazidim
aztreonam
among
enterobact
spp
e
cloaca
e
aerogen
primari
caus
nosocomi
pneumonia
frequent
colon
patient
receiv
cours
antibiot
resist
group
cephalosporin
among
pathogen
may
develop
within
day
treatment
proteu
mirabili
proteu
vulgari
act
opportunist
respiratori
pathogen
manner
similar
enterobact
spp
indoleposit
speci
pr
vulgari
may
undergo
singlestep
mutat
becom
constitut
highlevel
produc
enzym
manifest
resist
group
cephalosporin
ser
marcescen
preferenti
colon
respiratori
urinari
tract
associ
common
sourc
outbreak
pneumonia
set
inhal
therapi
contamin
bronchoscop
like
enterobacteriacea
organ
may
spread
patient
hand
transfer
healthcar
personnel
nonfer
gramneg
bacilli
import
ps
aeruginosa
acinetobact
spp
ps
aeruginosa
one
lead
caus
gramneg
pneumonia
common
mechan
infect
direct
contact
environment
reservoir
includ
respiratori
devic
contamin
nebul
humidifi
acinetobact
spp
also
result
seriou
nosocomi
infect
shown
import
caus
ventilatorassoci
pneumonia
h
influenza
frequent
colon
upper
respiratori
tract
individu
predispos
condit
copd
adult
infect
caus
nontyp
strain
h
influenza
along
str
pneumonia
often
isol
tracheal
secret
follow
intub
str
pneumonia
like
h
influenza
colon
oropharynx
although
predominantli
pathogen
associ
cap
str
pneumonia
recogn
increas
frequenc
caus
hospitalacquir
infect
anaerob
may
found
pathogen
patient
predispos
aspir
anaerob
implic
nosocomi
pneumonia
colon
oropharynx
fusobacterium
spp
prevotella
melaninogenica
bacteroid
ureolyticu
legionella
pneumophila
serogroup
common
legionella
spp
associ
cap
hospitalacquir
pneumonia
exact
mode
transmiss
controversi
evid
aspir
inhal
contamin
potabl
water
contamin
aerosol
report
sourc
infect
hospit
import
realiz
nosocomi
pneumonia
may
caus
multipl
pathogen
one
patient
emphas
need
broad
coverag
empir
treatment
initi
bartlett
colleagu
demonstr
one
pathogen
could
document
half
case
studi
pathogenesi
nosocomi
pneumonia
complex
pathogen
may
gain
access
lower
respiratori
tract
inhal
microaspir
silent
aspir
oropharyng
secret
gross
aspir
gastric
content
hematogen
spread
transloc
gastrointestin
tract
spread
contigu
focu
eg
pleural
space
direct
inocul
surgeri
certain
pathogen
mycobacteria
aspergillu
spp
inhal
aerosol
import
patient
mechan
ventil
contamin
humidif
reservoir
may
result
aspir
potenti
pathogen
directli
airway
import
mechan
howev
particularli
gramneg
rod
microaspir
bacteria
colon
oropharynx
studi
shown
oropharyng
colon
gramneg
rod
unusu
healthi
peopl
occur
increas
frequenc
underli
diseas
oropharyng
colon
establish
silent
aspir
potenti
virul
bacteria
eventu
result
overwhelm
host
defens
lung
develop
pneumonia
addit
oropharyngealpulmonari
rout
gastropulmonari
rout
also
suggest
mean
introduc
pathogen
distal
airway
normal
acid
ph
stomach
provid
hostil
environ
bacteria
render
stomach
content
virtual
steril
ph
bacteri
overgrowth
may
occur
howev
studi
stress
ulcer
prophylaxi
fail
demonstr
definit
correl
colon
stomach
bacteria
pneumonia
review
literatur
conclud
stomach
regard
amplifi
primari
sourc
pathogen
caus
pneumonia
oropharyngealpulmonari
rout
import
gastropulmonari
rout
patient
mechan
ventil
endotrach
tube
play
import
role
pathogenesi
ventilatorassoci
pneumonia
tube
breach
upper
airway
defens
inflat
cuff
allow
oropharyng
secret
contain
variou
pathogen
collect
eventu
pass
inflat
cuff
distal
airway
addit
tube
act
templat
upon
layer
biofilm
deposit
piec
biofilm
contain
million
bacteria
may
subsequ
break
reach
distal
airway
therebi
seed
remot
site
lung
much
said
discuss
clinic
manifest
cap
nurs
homeacquir
pneumonia
appli
nosocomi
pneumonia
find
vari
depend
upon
age
patient
sever
ill
cap
nurs
homeacquir
infect
symptom
may
constitut
nonspecif
local
respiratori
tract
cap
two
approach
may
use
clinic
invasivequantit
clinic
approach
pneumonia
defin
presenc
new
pulmonari
infiltr
unexplain
obviou
caus
plu
one
number
addit
featur
elev
temperatur
product
purul
sputum
leukocytosi
clinic
approach
rel
easi
straightforward
associ
signific
cost
overli
sensit
reliabl
discrimin
among
variou
caus
invasivequantit
approach
hand
gener
greater
precis
requir
special
train
laboratori
support
associ
signific
cost
potenti
seriou
advers
effect
whichev
approach
use
everi
patient
nosocomi
pneumonia
requir
care
histori
includ
risk
factor
specif
pathogen
physic
examin
posteroanterior
later
chest
radiograph
complet
blood
count
blood
chemistri
blood
cultur
either
oximetri
arteri
blood
gase
chest
radiographi
use
help
determin
extent
pneumonia
presenc
pleural
effus
multilobar
involv
cavit
rapid
radiograph
progress
indic
presenc
sever
infect
routin
blood
count
chemistri
may
indic
evid
endorgan
dysfunct
help
adjust
treatment
regimen
blood
cultur
may
use
identifi
pathogen
patient
nosocomi
pneumonia
presenc
pathogen
blood
indic
etiolog
agent
also
patient
increas
risk
complic
cours
serolog
normal
use
manag
individu
patient
nosocomi
pneumonia
may
howev
help
epidemiolog
purpos
although
like
case
patient
cap
valu
sputum
gram
stain
cultur
controversi
signific
problem
sensit
specif
test
studi
carri
patient
cap
howev
result
extrapol
patient
nosocomi
pneumonia
select
case
direct
stain
sputum
sampl
fungi
mycobacteria
direct
fluoresc
antibodi
stain
legionella
pneumophila
may
help
direct
therapi
invas
techniqu
perform
routin
patient
nosocomi
pneumonia
howev
invas
techniqu
consid
select
case
patient
receiv
appropri
empir
antimicrobi
coverag
fail
respond
certain
immunocompromis
patient
patient
altern
diagnosi
eg
carcinoma
suspect
number
method
develop
obtain
sampl
lower
respiratori
tract
secret
contamin
oropharyng
microorgan
endotrach
aspir
protect
cathet
aspir
protect
specimen
brush
bronchoalveolar
lavag
studi
claim
support
techniqu
suffer
lack
standard
make
comparison
difficult
best
discord
find
among
investig
studi
techniqu
make
difficult
practition
determin
effect
method
invas
test
includ
transthorac
needl
aspir
transbronchi
biopsi
thoracoscopi
open
lung
biopsi
one
studi
compar
invas
noninvas
strategi
manag
suspect
ventilatorassoci
pneumonia
show
statist
signific
reduct
mortal
sepsisrel
organ
failur
antibioticfre
day
cohort
manag
invas
diagnost
test
treatment
devis
antimicrobi
regimen
patient
pathogen
drug
consid
individu
interact
among
taken
account
includ
previou
histori
advers
reaction
particular
anyth
suggest
type
hypersensit
antimicrobi
increas
age
sinc
advers
drug
effect
common
elderli
peopl
macrolid
lincosamid
chloramphenicol
metronidazol
elimin
via
liver
antibiot
elimin
kidney
treat
women
childbear
age
import
determin
patient
pregnant
teratogen
fetotox
must
consid
ideal
narrowest
spectrum
agent
associ
least
toxic
lowest
cost
administ
pathogen
known
unfortun
empir
therapi
usual
norm
one
must
consid
like
pathogen
base
upon
local
epidemiolog
risk
factor
pneumonia
specif
pathogen
sever
ill
preval
resist
among
pathogen
variou
antimicrobi
must
also
consid
select
antibiot
first
step
select
agent
pathogen
known
like
suscept
consider
includ
pharmacokinet
pharmacodynam
properti
toxic
drug
interact
cost
depend
upon
class
antibiot
use
differ
pharmacokineticpharmacodynam
paramet
correl
less
close
clinic
therapeut
efficaci
drug
macrolid
clindamycin
time
antibiot
concentr
site
action
tissu
mic
organ
correl
best
efficaci
howev
aminoglycosid
fluoroquinolon
vancomycin
h
areaunderthecurvem
ratio
correl
best
higher
ratio
peak
serum
concentr
mic
c
max
mic
shown
prevent
emerg
resist
treatment
fluoroquinolon
aminoglycosid
furthermor
aminoglycosid
achiev
high
level
lung
tissu
problem
compound
fact
also
rel
inactiv
acid
ph
present
site
infect
lung
approach
manag
patient
nosocomi
pneumonia
take
account
risk
factor
sever
ill
time
onset
ill
risk
factor
infect
specif
pathogen
sever
ill
either
mild
moder
sever
time
onset
refer
earli
versu
late
ie
day
respect
base
upon
variabl
hierarch
approach
patient
nosocomi
pneumonia
develop
recogn
larg
number
bacteria
potenti
pathogen
core
group
organ
must
consid
patient
antimicrobi
coverag
must
provid
countri
produc
guidelin
local
use
reflect
variat
target
pathogen
choic
therapi
evid
base
surround
nosocomi
pneumonia
improv
variat
practic
like
continu
decis
select
agent
base
upon
host
pathogen
drugrel
issu
outlin
earlier
specif
issu
howev
deserv
comment
singleag
therapi
recommend
mani
situat
although
two
drug
use
achiev
synergist
addit
activ
ps
aeruginosa
data
support
routin
use
combin
therapi
bacteri
pathogen
nonneutropen
patient
patient
either
sever
ill
risk
factor
earli
onset
sever
ill
without
risk
factor
late
onset
combin
therapi
institut
patient
receiv
prior
antibiot
deep
suction
potenti
pathogen
recommend
antibiot
frequenc
penicillinresist
str
pneumonia
multidrugresist
str
pneumonia
increas
levofloxacin
moxifloxacin
prefer
ciprofloxacin
role
new
quinolon
gatifloxacin
establish
adapt
american
thorac
societi
combin
antibiot
therapi
aspir
bronchoscopi
sampl
fail
yield
ps
aeruginosa
oftenresist
pathogen
acinetobact
spp
treatment
may
modifi
singledrug
regimen
enterobact
spp
among
common
caus
gramneg
bacillari
hospitalacquir
pneumonia
major
concern
infect
caus
organ
presenc
group
cephalosporin
becom
hyperproduc
final
issu
durat
therapi
unfortun
appropri
design
random
control
trial
specif
address
issu
gener
consensu
howev
patient
sever
infect
caus
pathogen
ps
aeruginosa
acinetobact
spp
treat
minimum
day
wherea
patient
less
sever
infect
may
requir
day
treatment
